CD8A and neoplasm: Also recently, experiments using a head and neck squamous cell carcinoma (HNSC) model demonstrated that trametinib delays tumor initiation and progression by enhancing CD8+ T cell antitumor function and promoting development of long-term memory cells when combined with anti-PD-1 [79].